SCHEMBL358984

SCHEMBL358984

CCOC(OCC)C(C)C(OCC)OCC

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
THRB P10828 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14615983 0.87 LMNA (0.47) LMNATHRB
SCHEMBL16356371 0.87 LMNA (0.47) LMNATHRB
SCHEMBL7517448 0.84 LMNA (0.45) LMNATHRB
SCHEMBL7649563 0.82 LMNA (0.43) LMNATHRB
SCHEMBL22534482 0.82 LMNA (0.43) LMNATHRB
SCHEMBL1568155 0.81 THRB (0.57) LMNATHRBL3MBTL1
SCHEMBL4094836 0.79 LMNA (0.53) LMNATHRBL3MBTL1
SCHEMBL8589179 0.78 LMNA (0.45) LMNATHRB
SCHEMBL8588637 0.78 LMNA (0.45) LMNATHRB
SCHEMBL31633561 0.76 LMNA (0.50) LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111423366-B Preparation method of pirfenidone 山东汇海医药化工有限公司 2022-05-27 CN claimed
CN-111423366-A Preparation method of pirfenidone 山东汇海医药化工有限公司 2020-07-17 CN claimed
US-7553863-B2 Ultrapure 4-methylpyrazole Paladin Labs (Barbados) Inc. (BB) 2009-06-30 US claimed
EP-1948613-A2 PROCESS FOT THE PREPARATION OF ULTRAPURE 4-METHYLPYRAZOLE Orphan Medical Inc. (US) 2008-07-30 EP claimed
CN-101163679-A Process for preparing ultrapure 4-methylpyrazole ORPHAN MEDICAL INC (US) 2008-04-16 CN claimed
US-20070244330-A1 solution containing 4-methyl pyrazole containing less than 0.1% pyrazole, less than 10 ppm each of hydrazine and nitrobenzaldehyde; reacting propionaldehyde with triethyl orthoformate; reacting final intermediate with hydrazine to produce to produce 4-methylpyrazole; antidote for ethylene glycol posion ENDO OPERATIONS LIMITED (IE) 2007-10-18 US claimed
WO-2006115626-A2 PROCESS FOR THE PREPARATION OF ULTRAPURE 4-METHYLPRAZOLE ORPHAN MEDICAL, INC. (US) 2006-11-02 WO claimed
JP-10072554-A None JP disclosed
EP-4683921-A1 INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-01-28 EP disclosed
US-12351584-B2 Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-07-08 US disclosed
WO-2025079634-A1 CONDENSED RING COMPOUND, AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME 住友化学株式会社 2025-04-17 WO disclosed
WO-2024193542-A1 INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2024-09-26 WO disclosed
US-20230286993-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INT (DE) 2023-09-14 US disclosed
JP-H1072554-A CYANINE COLORANT FUJI PHOTO FILM CO LTD 1998-03-17 JP disclosed
US-5387502-A Containing specified cyanine dye sensitizer; high sensitivity, storage stability FUJI PHOTO FILM CO., LTD. (JP) 1995-02-07 US disclosed
US-4410733-A Preparation of acetals of malonaldehyde BASF AKTIENGESELLSCHAFT (DE) 1983-10-18 US disclosed
US-4283475-A Pentamethine thiopyrylium salts, process for production thereof, and photoconductive compositions containing said salts FUJI PHOTO FILM CO., LTD. (JP) 1981-08-11 US disclosed
US-4104273-A Derivatives of 3-cyano-pyrid-2-ones ROHM AND HAAS COMPANY (US) 1978-08-01 US disclosed
US-4075209-A Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate HOFFMANN-LA ROCHE, INC. (US) 1978-02-21 US disclosed
US-4028084-A Derivatives of 3-carboxy pyrid-2-ones ROHM AND HAAS COMPANY (US) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244330-A1 solution containing 4-methyl pyrazole containing less than 0.1% pyrazole, less than 10 ppm each of hydrazine and nitrobenzaldehyde; reacting propionaldehyde with triethyl orthoformate; reacting final intermediate with hydrazine to produce to produce 4-methylpyrazole; antidote for ethylene glycol posion CYP3A43, CYP3A5, CYP3A4 LMNA 3717/4885THRB 2287/4885L3MBTL1 4068/4885
US-20230286993-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE CNP, PDE3A, PDE5A LMNA 2620/4885THRB 3243/4885L3MBTL1 4533/4885
US-12351584-B2 Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide CNP, PDE3A, PDE5A LMNA 2620/4885THRB 3243/4885L3MBTL1 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.